Dakota Wealth Management lessened its holdings in Becton, Dickinson and Company (NYSE:BDX – Free Report) by 4.0% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 25,104 shares of the medical instruments supplier’s stock after selling 1,053 shares during the quarter. Dakota Wealth Management’s holdings in Becton, Dickinson and Company were worth $6,053,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also bought and sold shares of the company. WR Wealth Planners LLC raised its stake in shares of Becton, Dickinson and Company by 1.4% during the 2nd quarter. WR Wealth Planners LLC now owns 2,978 shares of the medical instruments supplier’s stock worth $696,000 after buying an additional 42 shares during the period. Clear Creek Financial Management LLC raised its position in Becton, Dickinson and Company by 5.1% during the second quarter. Clear Creek Financial Management LLC now owns 900 shares of the medical instruments supplier’s stock worth $210,000 after acquiring an additional 44 shares during the period. Sound Income Strategies LLC lifted its holdings in Becton, Dickinson and Company by 35.8% during the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 44 shares in the last quarter. Central Pacific Bank Trust Division grew its position in shares of Becton, Dickinson and Company by 22.5% in the third quarter. Central Pacific Bank Trust Division now owns 245 shares of the medical instruments supplier’s stock valued at $59,000 after purchasing an additional 45 shares during the period. Finally, Capital Advisors Ltd. LLC increased its stake in shares of Becton, Dickinson and Company by 3.6% during the second quarter. Capital Advisors Ltd. LLC now owns 1,394 shares of the medical instruments supplier’s stock worth $326,000 after purchasing an additional 48 shares in the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.
Becton, Dickinson and Company Stock Down 0.2 %
Shares of NYSE:BDX opened at $238.13 on Friday. The company has a market capitalization of $68.82 billion, a price-to-earnings ratio of 52.45, a PEG ratio of 1.79 and a beta of 0.42. Becton, Dickinson and Company has a 12-month low of $218.75 and a 12-month high of $259.92. The business has a 50-day moving average price of $237.43 and a 200 day moving average price of $235.18. The company has a current ratio of 1.85, a quick ratio of 1.36 and a debt-to-equity ratio of 0.70.
Wall Street Analyst Weigh In
Several research firms recently issued reports on BDX. StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Raymond James reduced their price objective on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research note on Friday, August 2nd. Stifel Nicolaus lifted their target price on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and increased their target price for the company from $255.00 to $275.00 in a research report on Tuesday, October 1st. Finally, Evercore ISI boosted their price target on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $282.63.
Read Our Latest Research Report on BDX
Becton, Dickinson and Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
See Also
- Five stocks we like better than Becton, Dickinson and Company
- 3 Best Fintech Stocks for a Portfolio Boost
- Texas Roadhouse Stock Steering for New Highs This Year
- Ride Out The Recession With These Dividend KingsĀ
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- 10 Best Airline Stocks to Buy
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.